Welcome to our dedicated page for Cellectis news (Ticker: CLLS), a resource for investors and traders seeking the latest updates and insights on Cellectis stock.
Cellectis S.A. (CLLS) news covers the activities of a clinical-stage biotechnology company focused on gene-edited cell and gene therapies. The company regularly issues updates on its allogeneic CAR-T pipeline, gene-editing technology advances, strategic collaborations, and financial position, providing a detailed view of how its programs evolve over time.
Investors and observers following Cellectis news can read about clinical data from key trials such as BALLI-01 for lasme-cel (UCART22) in relapsed or refractory B-cell acute lymphoblastic leukemia and NATHALI-01 for eti-cel (UCART20x22) in relapsed/refractory non-Hodgkin lymphoma. Press releases describe response rates, safety findings, and trial design features, as well as plans for pivotal Phase 2 development and data presentations at major scientific meetings.
Cellectis also publishes research and technology updates, including work on circular single-stranded DNA (CssDNA) as a non-viral donor template for gene insertion in hematopoietic stem and progenitor cells and studies of TALE base editors in primary T cells. These announcements highlight how the company applies its gene-editing platform beyond CAR-T therapies.
Additional news items address collaborations with partners such as AstraZeneca, Servier, Allogene, and Iovance, along with arbitration outcomes, financial results, cash runway disclosures, and monthly information on share capital and voting rights. By reviewing this news feed, readers can track both scientific progress and corporate developments that shape the outlook for Cellectis and its CLLS listing.
Cellectis (NASDAQ:CLLS) reported full-year 2025 results and a business update highlighting clinical progress and cash runway. Key clinical data: lasme-cel showed 100% ORR in the target Phase 2 population and pivotal interim readout expected Q4 2026; eti-cel showed 88% ORR and 63% CR at current dose. Financials: consolidated revenue $79.6M, consolidated net loss $67.6M, and cash and equivalents $211M providing runway into H2 2027.
Cellectis (NASDAQ: CLLS) will report fourth quarter and full year 2025 financial results for the period ending December 31, 2025 on March 19, 2026 after US market close. An investor conference call and webcast will follow on March 20, 2026 at 8:00 AM ET / 1:00 PM CET.
Dial-in details and a webcast link are provided for investors to access the company’s results and business update.
Cellectis (CLLS) reported its monthly share capital and voting rights as of 02/28/2026. The company shows a total of 100,590,994 shares and 105,825,561 total voting rights on Euronext Growth (ISIN FR0010425595).
Contact details for media and investor relations are provided for further information.
Cellectis (Euronext Growth: CLLS) reports monthly share capital and voting rights as of January 31, 2026. The company lists 100,590,994 total shares and 105,825,481 total voting rights. ISIN: FR0010425595. Contact details provided for media and investors.
Cellectis (NASDAQ:CLLS) outlined its 2026 strategy focused on advancing allogeneic CAR-T candidates and delivering multiple clinical catalysts. Key near-term milestones include a pivotal Phase 2 BALLI-01 interim analysis for lasme-cel (n=40) expected in Q4 2026, presentation of the full Phase 1 NATHALI-01 dataset for eti-cel in r/r NHL in Q4 2026, and a Q1 2026 IL-2 enrollment cohort for NATHALI-01. Phase 1 highlights for lasme-cel: ORR 68% (Process 2), 83% at RP2D, 100% in the target Phase 2 population, 56% CR/CRi with ~80% MRD-negativity, and 14.8 months median OS in MRD-neg CR/CRi. The company expects cash to fund operations into H2 2027 and continues collaborations with AstraZeneca, Servier/Allogene and Iovance.
Cellectis (Euronext Growth: CLLS) published its monthly information on share capital and voting rights as of December 31, 2025. The release lists the total number of shares and total voting rights recorded on that date.
- ISIN: FR0010425595
- Date: 12/31/2025
- Total shares: 100,339,441
- Total voting rights: 105,576,356
Contact details for media and investor relations were provided for further information.
Cellectis (NASDAQ: CLLS) announced an Arbitral Tribunal decision dated December 15, 2025 in its arbitration with Les Laboratoires Servier and IRIS SARL relating to the March 6, 2019 License Agreement.
The Tribunal ordered a partial termination of the License Agreement with respect to product UCART19 V1 (also called ALLO-501) and provided that Cellectis shall, at Allogene’s request, engage in good-faith discussions about granting a direct license to UCART19 V1. All other claims between the parties were dismissed.
Cellectis (NASDAQ:CLLS) presented updated Phase 1 NATHALI-01 data for eti-cel, an allogeneic dual CD20/CD22 CAR-T for relapsed/refractory non-Hodgkin lymphoma (r/r NHL).
At the current dose level, eti-cel showed an 88% overall response rate (ORR) and 63% complete response (CR) in n=8 patients. In vivo data suggested that low-dose interleukin-2 (IL-2) support may enhance CAR-T expansion and persistence without increasing toxicity. Cellectis will begin enrollment in an IL-2 support cohort in Q1 2026 and expects to present the full Phase 1 dataset in 2026. The poster will be posted on the company website.
Cellectis (CLLS) published its monthly information on share capital and voting rights as of November 30, 2025. The release reports the total number of shares as 100,325,454 and the total number of voting rights as 105,406,812. The announcement lists the listing market as Euronext Growth and the ISIN code as FR0010425595. Contact details for media and investor relations are provided for further information.
Cellectis (NASDAQ: CLLS) published a Nature Communications article on Nov 19, 2025 describing a non-viral gene insertion process using circular single-stranded DNA (CssDNA) donor templates combined with TALEN gene editing in hematopoietic stem and progenitor cells (HSPCs).
Key results: CssDNA produced 3–5x higher knock-in efficiency than linear ssDNA with efficiencies surpassing 40%; CssDNA enabled insertion at multiple HSPC loci and worked in primary T cells; CssDNA-edited HSPCs showed higher engraftment and maintenance of edits in a murine model versus AAV6-edited HSPCs.
This work positions CssDNA as an efficient non-viral strategy to expand durable gene and cell therapy options.